Biocon in pact with Tabuk Pharma to sell diabetes drugs in Middle East

Under this agreement, Tabuk Pharmaceuticals will market Biocon’s GLP-1 products across Saudi Arabia and other countries in the Middle East. Shares of Biocon Ltd ended at ₹372.50, up by ₹1.15, or 0.31%, on the BSE.

Leave a Reply

Your email address will not be published. Required fields are marked *